Pemetrexed plus Pembrolizumab

Phase 3Monoclonal antibody

HHunan Province Tumor Hospital

Pemetrexed plus Pembrolizumab is one of 43 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerRecruiting

Lung CancerPhase 3

Recruiting

Competition

Competitive Landscape

199 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

25 2

Beyfortus

BeiGene

Phase 3

10 3

Abraxane

Bristol-Myers Squibb

Phase 3

7 4

Imjudo

AstraZeneca

Phase 3

6 5

Tecentriq

Roche

Phase 3

6 6

Alecensa

Roche

Phase 3

3 7

Zepzelca

Jazz Pharmaceuticals

Phase 3

3 8

DATROWAY

Daiichi Sankyo

Phase 3

2 9

Tarlatamab-Dznl

Amgen

Phase 3

2 10

Lynparza

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Lung Cancer

NCT05055908

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Recruiting·HHunan Province Tumor Hospital·Phase 3·NCT05055908·12,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pemetrexed plus Pembrolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemetrexed plus Pembrolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemetrexed plus Pembrolizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hunan Province Tumor Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: HHunan Province Tumor Hospital

Pemetrexed plus Pembrolizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News